Document is current
Any future updates will be listed below
-
Authors
Inal, Ahmet
Sezer, Zafer
Pinarbasli, Onur
Bulut, Burcu
Reinsch, Martin
Martin, Wolfgang
Mazicioglu, Mumtaz M.
Koru, Selma Alime
-
Funding
Funding for this research was provided by:
ILKO pharmaceuticals
- License Information
-
More Information
Article History
Received: 21 August 2024
Accepted: 16 October 2024
First Online: 23 October 2024
Declarations
:
: The study was approved by an independent ethics committee-Ethics Committee for Bioavailability-Bioequivalence Trials of Erciyes University (date of approval: 15.06.2022; vote no: 2022/148) and the Turkish Medicines and Medical Devices Agency (TİTCK) of Turkish Ministry of Health, (date of approval: 01.07.2022, note no.: E-66175679-514.06.01-803603). The purpose of the investigation was fully disclosed to each subject in a written document and oral presentation by the principal investigator or one of the co-investigators. Then, each participant voluntarily signed the informed consent form.
: Not applicable.
: The authors declare no competing interests.
